MX2019011567A - Estatina para la prevención/reducción de daño relacionado con isquemia. - Google Patents
Estatina para la prevención/reducción de daño relacionado con isquemia.Info
- Publication number
- MX2019011567A MX2019011567A MX2019011567A MX2019011567A MX2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A
- Authority
- MX
- Mexico
- Prior art keywords
- ischemia
- prevention
- reduction
- related damage
- statin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se refiere, en términos generales, a la prevención y/o reducción del daño relacionado con isquemia. De manera más específica, la presente descripción se refiere a compuestos para ser utilizados en la prevención y/o reducción de daño relacionado con isquemia. Los compuestos son estatinas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164137.6A EP3381452A1 (en) | 2017-03-31 | 2017-03-31 | Statin for prevention/reduction of ischemia-related damage |
ES201730736 | 2017-05-26 | ||
PCT/EP2018/058158 WO2018178275A1 (en) | 2017-03-31 | 2018-03-29 | Statin for prevention/reduction of ischemia-related damage |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011567A true MX2019011567A (es) | 2020-01-21 |
Family
ID=61899251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019011567A MX2019011567A (es) | 2017-03-31 | 2018-03-29 | Estatina para la prevención/reducción de daño relacionado con isquemia. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200030288A1 (es) |
EP (1) | EP3600278B1 (es) |
CN (1) | CN110494134A (es) |
BR (1) | BR112019020353A2 (es) |
CA (1) | CA3058250A1 (es) |
DK (1) | DK3600278T3 (es) |
ES (1) | ES2877646T3 (es) |
MX (1) | MX2019011567A (es) |
PL (1) | PL3600278T3 (es) |
RU (1) | RU2768889C2 (es) |
WO (1) | WO2018178275A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516126A (zh) * | 2020-11-20 | 2021-03-19 | 南方医科大学南方医院 | 普伐他汀的新用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999010499A1 (en) | 1997-08-22 | 1999-03-04 | Dsm N.V. | Statin production by fermentation |
CA2485989A1 (en) * | 2002-05-17 | 2003-11-27 | Esperion Therapeutics, Inc. | Methods and compositions for the treatment of ischemic reperfusion |
US7166638B2 (en) | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
CN100502870C (zh) * | 2005-07-07 | 2009-06-24 | 安徽省现代中药研究中心 | 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物 |
AU2007209859A1 (en) * | 2006-01-30 | 2007-08-09 | Israel Ben David Bryson | Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients |
EP2134696B1 (en) | 2007-04-03 | 2017-05-17 | LEK Pharmaceuticals d.d. | Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof |
EP2271335A1 (en) | 2008-04-29 | 2011-01-12 | DSM IP Assets B.V. | Improved statin production |
CN102171328A (zh) | 2008-09-24 | 2011-08-31 | 帝斯曼知识产权资产管理有限公司 | 经改进的斯达汀生产 |
US10028975B2 (en) * | 2010-10-19 | 2018-07-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating ischemia-reperfusion injury |
EP2949324A1 (en) * | 2014-05-27 | 2015-12-02 | Consorci Institut Catala de Ciencies Cardiovasculars | Prevention and/or treatment of ischemia/reperfusion injury |
-
2018
- 2018-03-29 ES ES18715625T patent/ES2877646T3/es active Active
- 2018-03-29 RU RU2019134491A patent/RU2768889C2/ru active
- 2018-03-29 CA CA3058250A patent/CA3058250A1/en active Pending
- 2018-03-29 EP EP18715625.2A patent/EP3600278B1/en active Active
- 2018-03-29 US US16/498,813 patent/US20200030288A1/en active Pending
- 2018-03-29 BR BR112019020353A patent/BR112019020353A2/pt unknown
- 2018-03-29 DK DK18715625.2T patent/DK3600278T3/da active
- 2018-03-29 WO PCT/EP2018/058158 patent/WO2018178275A1/en unknown
- 2018-03-29 MX MX2019011567A patent/MX2019011567A/es unknown
- 2018-03-29 CN CN201880023430.1A patent/CN110494134A/zh active Pending
- 2018-03-29 PL PL18715625T patent/PL3600278T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
PL3600278T3 (pl) | 2021-08-02 |
US20200030288A1 (en) | 2020-01-30 |
BR112019020353A2 (pt) | 2020-04-28 |
RU2019134491A (ru) | 2021-04-30 |
WO2018178275A1 (en) | 2018-10-04 |
RU2019134491A3 (es) | 2021-07-16 |
EP3600278A1 (en) | 2020-02-05 |
CA3058250A1 (en) | 2018-10-04 |
DK3600278T3 (da) | 2021-04-26 |
EP3600278B1 (en) | 2021-01-27 |
CN110494134A (zh) | 2019-11-22 |
RU2768889C2 (ru) | 2022-03-25 |
ES2877646T3 (es) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502810A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
PH12015502091A1 (en) | Cdc7 inhibitors | |
NZ742742A (en) | Compositions and methods for inhibiting arginase activity | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
MX2021011946A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
AU2018301696A8 (en) | Heterocyclic inhibitors of ATR kinase | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF | |
JO3488B1 (ar) | مثبط أرورا a كيناز | |
MX2017002323A (es) | Variantes de desintegrina y usos farmaceuticos de las mismas. | |
MX2019011567A (es) | Estatina para la prevención/reducción de daño relacionado con isquemia. | |
EP3694503A4 (en) | NOVEL SUBSTITUTED CYCLOBUTYLPYRIDINE AND CYCLOBUTYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO) | |
EP3694506A4 (en) | NEW SUBSTITUTED PHENYLOXETANE AND PHENYLTETRAHYDROFURANE COMPOUNDS AS INHIBITORS OF INDOLAMINE 2,3-DIOXYGENASE (IDO) | |
WO2015144977A8 (en) | Trpa1 modulators | |
PH12017501897A1 (en) | 2-thiopyrimidinones | |
GEP20207170B (en) | Pharmaceutical composition comprising an hmg-coa reductase inhibitor and an eca inhibitor | |
EP3381452A8 (en) | Statin for prevention/reduction of ischemia-related damage |